{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:21:24Z","timestamp":1793967684291,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Due to nusinersen\u2019s route of administration and dosing regimen, the spinal muscular atrophy (SMA) population and\/or their caregivers need to travel to hospitals and work around physician\u2019s schedules to receive treatment. Real-world studies with large sample sizes on administration practice and adherence rate of nusinersen are lacking, especially in non-United States settings. This study aimed to investigate the administration practice and adherence of nusinersen in Chinese adults with 5q-SMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An ambispective, multicenter registry of adults with 5q-SMA in China provided the longitudinal data for this analysis. Nusinersen was scheduled on Day 0, 14, 28, 63, and every 4 months thereafter. Adherence rate was calculated at dose level. A dose was deemed adherent if the interval between the current and preceding dose aligned with the standard dosing regimen, allowing a grace period of \u00b1\u20097 days for doses 2 through 4 and \u00b1\u200928 days for all subsequent doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 177 participants receiving nusinersen with 1,329 doses were included in the study. All injections were given in inpatient setting with no ventilatory support or sedation needed. Only one injection (0.1%) was performed under general anesthesia. Almost all (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091,322, 99.5%) injections were given through interspinous lumbar puncture. Injections in participants with scoliosis require more imaging techniques for guiding administration compared with those in participants without scoliosis (68.3% vs. 29.1%). Ultrasound was the most commonly used guide before or during administration (674\/708). The adherence rate was 92.8% (1,062\/1,144). The median inter-dose intervals aligned well with dosing schedule, with 14 days for Dose 2 and 3, 35 days for Dose 4, and 120\u2013124 days for Dose 5 to 10 as maintenance doses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings characterize the patterns of nusinersen administration practice, demonstrating high real-world adherence to nusinersen administration in Chinese adults with 5q-SMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The registry was registered at clinicaltrials.gov (NCT05618379) on November 16\n                      <jats:sup>th<\/jats:sup>\n                      , 2022.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-04730-x","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:16:38Z","timestamp":1772241398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Administration practice and adherence of nusinersen in adults with 5q-spinal muscular atrophy in China: an ambispective multicenter study"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaoli","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daojun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maerhaba","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"10","key":"4730_CR1","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.nmd.2019.08.007","volume":"29","author":"S Bortolani","year":"2019","unstructured":"Bortolani S, Stura G, Ventilii G, Vercelli L, Rolle E, Ricci F, Bergui M, Mongini T. Intrathecal administration of Nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: transforaminal versus conventional approach. Neuromuscul Disorders: NMD. 2019;29(10):742\u20136. https:\/\/doi.org\/10.1016\/j.nmd.2019.08.007.","journal-title":"Neuromuscul Disorders: NMD"},{"key":"4730_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejpn.2021.02.009","volume":"31","author":"L Carrera-Garc\u00eda","year":"2021","unstructured":"Carrera-Garc\u00eda L, Muchart J, Lazaro JJ, Exp\u00f3sito-Escudero J, Cuadras D, Medina J, Bosch de Basea M, Colomer J, Jimenez-Mallebrera C, Ortez C, Natera-de Benito D, Nascimento A. Pediatric SMA patients with complex spinal anatomy: implementation and evaluation of a decision-tree algorithm for administration of Nusinersen. Eur J Pediatr Neurology: EJPN: Official J Eur Pediatr Neurol Soc. 2021;31:92\u2013101. https:\/\/doi.org\/10.1016\/j.ejpn.2021.02.009.","journal-title":"Eur J Pediatr Neurology: EJPN: Official J Eur Pediatr Neurol Soc"},{"issue":"1","key":"4730_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/mus.26899","volume":"62","author":"MS Cartwright","year":"2020","unstructured":"Cartwright MS, Ward ZT, White EP, West TG. Intrathecal delivery of Nusinersen in individuals with complicated spines. Muscle Nerve. 2020;62(1):114\u20138. https:\/\/doi.org\/10.1002\/mus.26899.","journal-title":"Muscle Nerve"},{"key":"4730_CR4","doi-asserted-by":"publisher","first-page":"175628641988761","DOI":"10.1177\/1756286419887616","volume":"13","author":"I Cordts","year":"2020","unstructured":"Cordts I, Lingor P, Friedrich B, Pernpeintner V, Zimmer C, Deschauer M, Maegerlein C. Intrathecal Nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy. Ther Adv Neurol Disord. 2020;13:1756286419887616. https:\/\/doi.org\/10.1177\/1756286419887616.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"4730_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1017\/cjn.2024.49","volume":"52","author":"I C\u00f4t\u00e9","year":"2025","unstructured":"C\u00f4t\u00e9 I, Hodgkinson V, Nury M, Bastenier-Boutin L, Rodrigue X. A Real-World study of Nusinersen effects in adults with spinal muscular atrophy type 2 and 3. Can J Neurol Sci \/ J Canadien Des Sci Neurologiques. 2025;52(1):119\u201328. https:\/\/doi.org\/10.1017\/cjn.2024.49.","journal-title":"Can J Neurol Sci \/ J Canadien Des Sci Neurologiques"},{"key":"4730_CR6","unstructured":"DaiY, Zhao Y, Shang H, Zhu W, Yao X, Meng Q et al. A national registry for adult patients with spinal muscular atrophy in China: Preliminary report of design, progress and patient characteristics [Abstract]. The 21st Annual Meeting of Asian Oceanian Myology Center; Oct 2023; Shanghai, China. 2023. (n.d.). https:\/\/www.aomc.info\/report\/Program2023.pdf. Accessed 02 Feb 2026."},{"issue":"8","key":"4730_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/WNL.0000000000006026","volume":"91","author":"BT Darras","year":"2018","unstructured":"Darras BT, De Vivo DC. Precious SMA natural history data: A benchmark to measure future treatment successes. Neurology. 2018;91(8):337\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000006026.","journal-title":"Neurology"},{"key":"4730_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.vhri.2022.08.015","volume":"34","author":"C Duan","year":"2023","unstructured":"Duan C, Ai D, Xu Q, Sui B, Zhao K. Budget impact analysis of Nusinersen for spinal muscular atrophy in China. Value Health Reg Issues. 2023;34:9\u201313. https:\/\/doi.org\/10.1016\/j.vhri.2022.08.015.","journal-title":"Value Health Reg Issues"},{"issue":"5","key":"4730_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3233\/JND-210768","volume":"9","author":"L Elman","year":"2022","unstructured":"Elman L, Youn B, Proud CM, Frey MR, Ajroud-Driss S, McCormick ME, Michelson D, Cartwright MS, Heiman-Patterson T, Choi JM, Chandak A, Khachatryan A, Martinez M, Paradis AD. Real-world adherence to Nusinersen in adults with spinal muscular atrophy in the US: A Multi-site chart review study. J Neuromuscul Dis. 2022;9(5):655\u201360. https:\/\/doi.org\/10.3233\/JND-210768.","journal-title":"J Neuromuscul Dis"},{"key":"4730_CR10","unstructured":"European Commission. (2026, January). Spinraza (nusinersen) \u2013 Summary of Product Characteristics (High\u2013dose 50\u00a0mg \/ 28\u00a0mg regimen). Community Register of Medicinal Products. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2026\/20260109168308\/anx_168308_en.pdf. Accessed 02 Feb 2026."},{"issue":"6","key":"4730_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1055\/s-0040-1715481","volume":"51","author":"M Flotats-Bastardas","year":"2020","unstructured":"Flotats-Bastardas M, Hahn A, Schwartz O, Linsler S, Meyer S, Kolodziej M, Koehler C. Multicenter experience with Nusinersen application via an intrathecal Port and catheter system in spinal muscular atrophy. Neuropediatrics. 2020;51(6):401\u20136. https:\/\/doi.org\/10.1055\/s-0040-1715481.","journal-title":"Neuropediatrics"},{"issue":"3","key":"4730_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12325-022-02376-y","volume":"40","author":"D Fox","year":"2023","unstructured":"Fox D, To TM, Seetasith A, Patel AM, Iannaccone ST. Adherence and persistence to Nusinersen for spinal muscular atrophy: A US Claims-Based analysis. Adv Therapy. 2023;40(3):903\u201319. https:\/\/doi.org\/10.1007\/s12325-022-02376-y.","journal-title":"Adv Therapy"},{"issue":"12","key":"4730_CR13","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1007\/s12325-021-01938-w","volume":"38","author":"M Gauthier-Loiselle","year":"2021","unstructured":"Gauthier-Loiselle M, Cloutier M, Toro W, Patel A, Shi S, Davidson M, Bischof M, LaMarca N, Dabbous O. Nusinersen for spinal muscular atrophy in the united states: findings from a retrospective claims database analysis. Adv Therapy. 2021;38(12):5809\u201328. https:\/\/doi.org\/10.1007\/s12325-021-01938-w.","journal-title":"Adv Therapy"},{"issue":"2","key":"4730_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s13311-022-01200-3","volume":"19","author":"M Gavriilaki","year":"2022","unstructured":"Gavriilaki M, Moschou M, Papaliagkas V, Notas K, Chatzikyriakou E, Papagiannopoulos S, Arnaoutoglou M, Kimiskidis VK. Nusinersen in adults with 5q spinal muscular atrophy: A systematic review and Meta-analysis. Neurotherapeutics. 2022;19(2):464\u201375. https:\/\/doi.org\/10.1007\/s13311-022-01200-3.","journal-title":"Neurotherapeutics"},{"key":"4730_CR15","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.lanepe.2024.100862","volume":"39","author":"R G\u00fcnther","year":"2024","unstructured":"G\u00fcnther R, Wurster CD, Brakemeier S, Osmanovic A, Schreiber-Katz O, Petri S, Uzelac Z, Hiebeler M, Thiele S, Walter MC, Weiler M, Kessler T, Freigang M, Lapp HS, Cordts I, Lingor P, Deschauer M, Hahn A, Martakis K, Hagenacker T. Long-term efficacy and safety of Nusinersen in adults with 5q spinal muscular atrophy: A prospective European multinational observational study. Lancet Reg Health - Europe. 2024;39:100862. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100862.","journal-title":"Lancet Reg Health - Europe"},{"issue":"7","key":"4730_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0883073815627882","volume":"31","author":"M Hach\u00e9","year":"2016","unstructured":"Hach\u00e9 M, Swoboda KJ, Sethna N, Farrow-Gillespie A, Khandji A, Xia S, Bishop KM. Intrathecal injections in children with spinal muscular atrophy: Nusinersen clinical trial experience. J Child Neurol. 2016;31(7):899\u2013906. https:\/\/doi.org\/10.1177\/0883073815627882.","journal-title":"J Child Neurol"},{"issue":"3","key":"4730_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/CND.0000000000000333","volume":"22","author":"ST Iannaccone","year":"2021","unstructured":"Iannaccone ST, Paul D, Castro D, Weprin B, Swift D. Delivery of Nusinersen through an Ommaya reservoir in spinal muscular atrophy. J Clin Neuromuscul Dis. 2021;22(3):129\u201334. https:\/\/doi.org\/10.1097\/CND.0000000000000333.","journal-title":"J Clin Neuromuscul Dis"},{"key":"4730_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S239603","volume":"14","author":"MC Keinath","year":"2021","unstructured":"Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: Mutations, Testing, and clinical relevance. Application Clin Genet. 2021;14:11\u201325. https:\/\/doi.org\/10.2147\/TACG.S239603.","journal-title":"Application Clin Genet"},{"issue":"2","key":"4730_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3171\/2019.2.SPINE181366","volume":"31","author":"D Ko","year":"2019","unstructured":"Ko D, Blatt D, Karam C, Gupta K, Raslan AM. Lumbar laminotomy for the intrathecal administration of Nusinersen for spinal muscular atrophy: technical note and outcomes. J Neurosurgery: Spine. 2019;31(2):217\u201321. https:\/\/doi.org\/10.3171\/2019.2.SPINE181366.","journal-title":"J Neurosurgery: Spine"},{"issue":"1","key":"4730_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13023-023-02769-4","volume":"18","author":"A \u0141usakowska","year":"2023","unstructured":"\u0141usakowska A, W\u00f3jcik A, Fr\u0105czek A, Aragon-Gawi\u0144ska K, Potulska-Chromik A, Baranowski P, Nowak R, Rosiak G, Milczarek K, Konecki D, Gierlak-W\u00f3jcicka Z, Burlewicz M, Kostera-Pruszczyk A. Long-term Nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: A real-world experience. Orphanet J Rare Dis. 2023;18(1):230. https:\/\/doi.org\/10.1186\/s13023-023-02769-4.","journal-title":"Orphanet J Rare Dis"},{"key":"4730_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejpn.2025.01.005","volume":"54","author":"B Mansilla Fern\u00e1ndez","year":"2025","unstructured":"Mansilla Fern\u00e1ndez B, Sol\u00eds P, Garc\u00eda Romero JF, Fernandez-Garcia MDM, Rom\u00e1n MA, De Arag\u00f3n M, Benito C, F., Pascual P, S. I. Difficulty of administration of Nusinersen in complex-column spinal muscular atrophy: new alternative technique by means of cervical intrathecal access through an Ommaya reservoir. Eur J Pediatr Neurol. 2025;54:107\u201312. https:\/\/doi.org\/10.1016\/j.ejpn.2025.01.005.","journal-title":"Eur J Pediatr Neurol"},{"issue":"2","key":"4730_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1590\/0004-282X-ANP-2020-0200","volume":"79","author":"R Mendon\u00e7a","year":"2021","unstructured":"Mendon\u00e7a R, de Fernandes H, Pinto HDS, Matsui RBS, J\u00fanior C, Polido GJ, Silva AMS, da, Grossklauss LF, Reed UC, Zanoteli E. Managing intrathecal administration of Nusinersen in adolescents and adults with 5q-spinal muscular atrophy and previous spinal surgery. Arq Neuropsiquiatr. 2021;79(2):127\u201332. https:\/\/doi.org\/10.1590\/0004-282X-ANP-2020-0200.","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"4730_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12939-018-0799-8","volume":"17","author":"Y Miao","year":"2018","unstructured":"Miao Y, Gu J, Zhang L, He R, Sandeep S, Wu J. Improving the performance of social health insurance system through increasing outpatient expenditure reimbursement ratio: A quasi-experimental evaluation study from rural China. Int J Equity Health. 2018;17(1):89. https:\/\/doi.org\/10.1186\/s12939-018-0799-8.","journal-title":"Int J Equity Health"},{"issue":"20","key":"4730_CR24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1212\/WNL.0000000000006502","volume":"91","author":"D Michelson","year":"2018","unstructured":"Michelson D, Ciafaloni E, Ashwal S, Lewis E, Narayanaswami P, Oskoui M, Armstrong MJ. Evidence in focus: Nusinersen use in spinal muscular atrophy: report of the guideline Development, Dissemination, and implementation subcommittee of the American academy of neurology. Neurology. 2018;91(20):923\u201333. https:\/\/doi.org\/10.1212\/WNL.0000000000006502.","journal-title":"Neurology"},{"issue":"12","key":"4730_CR25","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s00247-018-4206-9","volume":"48","author":"MA Mousa","year":"2018","unstructured":"Mousa MA, Aria DJ, Schaefer CM, Kaye RD, Abruzzo TA, Bernes SM, Willard SD, Riemann MC, Towbin RB. A comprehensive institutional overview of intrathecal Nusinersen injections for spinal muscular atrophy. Pediatr Radiol. 2018;48(12):1797\u2013805. https:\/\/doi.org\/10.1007\/s00247-018-4206-9.","journal-title":"Pediatr Radiol"},{"issue":"5","key":"4730_CR26","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3174\/ajnr.A5596","volume":"39","author":"DR Nascene","year":"2018","unstructured":"Nascene DR, Ozutemiz C, Estby H, McKinney AM, Rykken JB. Transforaminal lumbar puncture: an alternative technique in patients with challenging Access. AJNR. Am J Neuroradiol. 2018;39(5):986\u201391. https:\/\/doi.org\/10.3174\/ajnr.A5596.","journal-title":"Am J Neuroradiol"},{"issue":"3","key":"4730_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5863\/1551-6776-24.3.194","volume":"24","author":"EE Neil","year":"2019","unstructured":"Neil EE, Bisaccia EK. Nusinersen: A novel antisense oligonucleotide for the treatment of spinal muscular atrophy. J Pediatr Pharmacol Ther. 2019;24(3):194\u2013203. https:\/\/doi.org\/10.5863\/1551-6776-24.3.194.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"4730_CR28","unstructured":"(2019,February). Nusinersen Sodium Injection, Biogen Netherlands BV. https:\/\/www.biogen.com.cn\/content\/dam\/corporate\/apac\/china\/zh-cn\/disease-areas\/sma\/%E8%AF%BA%E8%A5%BF%E9%82%A3%E7%94%9F%E9%92%A0%E6%B3%A8%E5%B0%84%E6%B6%B2%E8%AF%B4%E6%98%8E%E4%B9%A6_202405.pdf. Accessed 02 Feb 2026."},{"issue":"6","key":"4730_CR29","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5152\/dir.2020.19607","volume":"26","author":"C \u00d6z\u00fctemiz","year":"2020","unstructured":"\u00d6z\u00fctemiz C, Karachunski P, Nascene DR. Nusinersen injections in adults and children with spinal muscular atrophy: A single-center experience. Diagn Interv Radiol (Ankara Turkey). 2020;26(6):596\u2013602. https:\/\/doi.org\/10.5152\/dir.2020.19607.","journal-title":"Diagn Interv Radiol (Ankara Turkey)"},{"issue":"3","key":"4730_CR30","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1159\/000519831","volume":"13","author":"V Papaliagkas","year":"2021","unstructured":"Papaliagkas V, Foroglou N, Toulios P, Moschou M, Gavriilaki M, Notas K, Chatzikyriakou E, Zafeiridou G, Arnaoutoglou M, Kimiskidis VK. Intrathecal administration of Nusinersen using the Ommaya reservoir in an adult with 5q-Related spinal muscular atrophy type 1 and severe spinal deformity. Case Rep Neurol. 2021;13(3):710\u20135. https:\/\/doi.org\/10.1159\/000519831.","journal-title":"Case Rep Neurol"},{"issue":"6","key":"4730_CR31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/jmg.15.6.409","volume":"15","author":"J Pearn","year":"1978","unstructured":"Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet. 1978;15(6):409\u201313. https:\/\/doi.org\/10.1136\/jmg.15.6.409.","journal-title":"J Med Genet"},{"issue":"1","key":"4730_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12887-024-05290-0","volume":"25","author":"J Peng","year":"2025","unstructured":"Peng J, Yao X, Luo R, Wang X, Wu L, Zhong J, Jin R, Lu X, Liang J, Hong S, Yang L, Zhang X, Mao S, Tao Z, Hu J, Sun D, Wang H, Zhang L, Xia Y, Chen K, Wang Y. Administration practices of and adherence to Nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China. BMC Pediatr. 2025;25(1):239. https:\/\/doi.org\/10.1186\/s12887-024-05290-0.","journal-title":"BMC Pediatr"},{"key":"4730_CR33","unstructured":"Pharmaceuticals and Medical Devices Agency. (2017, August). SPINRAZA Intrathecal injection. PMDA Search. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/630499_1190403A1022_1_10. Accessed 02 Feb 2026."},{"key":"4730_CR34","doi-asserted-by":"publisher","unstructured":"Rare Disease Society of Chinese Research Hospital Association. China alliance for rare diseases, Beijing society of rare disease clinical care and Accessibility, & China expert group for clinical practice guideline for adolescent & adult patients with spinal muscular atrophy. (2023). clinical practice guideline for adolescent & adult patients with spinal muscular atrophy. J Rare Dis; 2(2): 231\u201355. https:\/\/doi.org\/10.12376\/j.issn.2097-0501.2023.02.010","DOI":"10.12376\/j.issn.2097-0501.2023.02.010"},{"issue":"4","key":"4730_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00234-021-02643-9","volume":"63","author":"G Rosiak","year":"2021","unstructured":"Rosiak G, Lusakowska A, Milczarek K, Konecki D, Fraczek A, Rowinski O, Kostera-Pruszczyk A. Ultra-low radiation dose protocol for CT-guided intrathecal Nusinersen injections for patients with spinal muscular atrophy and severe scoliosis. Neuroradiology. 2021;63(4):539\u201345. https:\/\/doi.org\/10.1007\/s00234-021-02643-9.","journal-title":"Neuroradiology"},{"issue":"3","key":"4730_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00439-019-01983-0","volume":"138","author":"C Ruhno","year":"2019","unstructured":"Ruhno C, McGovern VL, Avenarius MR, Snyder PJ, Prior TW, Nery FC, Muhtaseb A, Roggenbuck JS, Kissel JT, Sansone VA, Siranosian JJ, Johnstone AJ, Nwe PH, Zhang RZ, Swoboda KJ, Burghes AH M. Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype. Hum Genet. 2019;138(3):241\u201356. https:\/\/doi.org\/10.1007\/s00439-019-01983-0.","journal-title":"Hum Genet"},{"issue":"3","key":"4730_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2478\/raon-2022-0033","volume":"56","author":"V Salapura","year":"2022","unstructured":"Salapura V, Snoj Z, Leonardis L, Koritnik B, Kostadinova V. Cone-beam computed tomography guided Nusinersen administrations in adult spinal muscular atrophy patients with challenging access: A single- center experience. Radiol Oncol. 2022;56(3):319\u201325. https:\/\/doi.org\/10.2478\/raon-2022-0033.","journal-title":"Radiol Oncol"},{"issue":"7","key":"4730_CR38","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/ene.14245","volume":"27","author":"S Spiliopoulos","year":"2020","unstructured":"Spiliopoulos S, Reppas L, Zompola C, Palaiodimou L, Papadopoulou M, Filippiadis D, Palialexis K, Ploussi A, Efstathopoulos E, Tsivgoulis G, Brountzos E. Computed-tomography-guided transforaminal intrathecal Nusinersen injection in adults with spinal muscular atrophy type 2 and severe spinal deformity. Feasibility, safety and radiation exposure considerations. Eur J Neurol. 2020;27(7):1343\u20139. https:\/\/doi.org\/10.1111\/ene.14245.","journal-title":"Eur J Neurol"},{"key":"4730_CR39","unstructured":"SPINRAZA (nusinersen) injection. Package Insert. (2016, December). Biogen Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf.\u00a0Accessed 02 Feb 2026."},{"key":"4730_CR40","doi-asserted-by":"publisher","first-page":"175628641880324","DOI":"10.1177\/1756286418803246","volume":"11","author":"B Stolte","year":"2018","unstructured":"Stolte B, Totzeck A, Kizina K, Bolz S, Pietruck L, M\u00f6nninghoff C, Guberina N, Oldenburg D, Forsting M, Kleinschnitz C, Hagenacker T. Feasibility and safety of intrathecal treatment with Nusinersen in adult patients with spinal muscular atrophy. Ther Adv Neurol Disord. 2018;11:1756286418803246. https:\/\/doi.org\/10.1177\/1756286418803246.","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"4730_CR41","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/ene.15501","volume":"29","author":"JF V\u00e1zquez-Costa","year":"2022","unstructured":"V\u00e1zquez-Costa JF, Povedano M, Nascimiento\u2010Osorio AE, Escribano M, Kapetanovic Garcia A, Dominguez S, Exposito R, Gonz\u00e1lez JM, Marco L, Medina Castillo C, Muelas J, De Benito NN, \u00d1ungo D, Garz\u00f3n NC, Castellano P, Sevilla I, T., Herv\u00e1s D. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts\u2019 study. Eur J Neurol. 2022;29(11):3337\u201346. https:\/\/doi.org\/10.1111\/ene.15501.","journal-title":"Eur J Neurol"},{"issue":"2","key":"4730_CR42","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ene.14586","volume":"28","author":"D Veiga-Canuto","year":"2021","unstructured":"Veiga-Canuto D, Cifri\u00e1n-P\u00e9rez M, Pitarch-Castellano I, V\u00e1zquez-Costa JF, Aparici F. Ultrasound-guided lumbar puncture for Nusinersen administration in spinal muscular atrophy patients. Eur J Neurol. 2021;28(2):676\u201380. https:\/\/doi.org\/10.1111\/ene.14586.","journal-title":"Eur J Neurol"},{"issue":"2","key":"4730_CR43","doi-asserted-by":"publisher","first-page":"e018440","DOI":"10.1136\/bmjopen-2017-018440","volume":"8","author":"H Wang","year":"2018","unstructured":"Wang H, Zhang D, Hou Z, Yan F, Hou Z. Association between social health insurance and choice of hospitals among internal migrants in china: A National cross-sectional study. BMJ Open. 2018;8(2):e018440. https:\/\/doi.org\/10.1136\/bmjopen-2017-018440.","journal-title":"BMJ Open"},{"issue":"9","key":"4730_CR44","doi-asserted-by":"publisher","first-page":"6004","DOI":"10.1007\/s00415-024-12567-y","volume":"271","author":"N Wang","year":"2024","unstructured":"Wang N, Hu Y, Jiao K, Cheng N, Sun J, Tang J, Song J, Sun C, Wang T, Wang K, Qiao K, Xi J, Zhao C, Yu L, Zhu W. Long-term impact of Nusinersen on motor and electrophysiological outcomes in adolescent and adult spinal muscular atrophy: insights from a multicenter retrospective study. J Neurol. 2024;271(9):6004\u201314. https:\/\/doi.org\/10.1007\/s00415-024-12567-y.","journal-title":"J Neurol"},{"issue":"1","key":"4730_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00415-018-9124-0","volume":"266","author":"CD Wurster","year":"2019","unstructured":"Wurster CD, Winter B, Wollinsky K, Ludolph AC, Uzelac Z, Witzel S, Schocke M, Schneider R, Kocak T. Intrathecal administration of Nusinersen in adolescent and adult SMA type 2 and 3 patients. J Neurol. 2019;266(1):183\u201394. https:\/\/doi.org\/10.1007\/s00415-018-9124-0.","journal-title":"J Neurol"},{"key":"4730_CR46","doi-asserted-by":"publisher","unstructured":"Youn B, Proud CM, Wang N, Hou Q, Viscidi E, Eaton S, Paradis AD, Neville BA, Johnson NB.Examining Real-World Adher ence to Nusinersen for the Treatment of Spinal Muscular Atrophy Using Two Large US Data Sources. Adv Therapy. 2023;40(3):1129\u201340. https:\/\/doi.org\/10.1007\/s12325-022-02414-9.","DOI":"10.1007\/s12325-022-02414-9"},{"issue":"5","key":"4730_CR47","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/mus.27400","volume":"64","author":"BA Zanfini","year":"2021","unstructured":"Zanfini BA, Catarci S, Patanella AK, Pane M, Frassanito L, Filipponi E, Mercuri E, Sabatelli M, Draisci G. Ultrasound assisted lumbar intrathecal administration of Nusinersen in adult patients with spinal muscular atrophy: A case series. Muscle Nerve. 2021;64(5):594\u20139. https:\/\/doi.org\/10.1002\/mus.27400.","journal-title":"Muscle Nerve"},{"issue":"5","key":"4730_CR48","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52(5):518\u201323. https:\/\/doi.org\/10.1001\/archneur.1995.00540290108025.","journal-title":"Arch Neurol"},{"issue":"5","key":"4730_CR49","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1212\/CPJ.0000000000000718","volume":"9","author":"CD Zingariello","year":"2019","unstructured":"Zingariello CD, Brandsema J, Drum E, Henderson AA, Dubow S, Glanzman AM, Mayer O, Yum SW, Kichula EA. A multidisciplinary approach to dosing Nusinersen for spinal muscular atrophy. Neurol Clin Pract. 2019;9(5):424\u201332. https:\/\/doi.org\/10.1212\/CPJ.0000000000000718.","journal-title":"Neurol Clin Pract"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04730-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04730-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04730-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:03:15Z","timestamp":1781636595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04730-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4730"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04730-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Review Committee of the Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, the leading site of the study (approval no. I-22PJ323) on September 20, 2022, and ethics committees of all participating sites. All participants provided written informed consent prior to enrolment in the study. This research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LZ and MM are employees of Biogen and may hold stock in Biogen. KC is an employee of IQVIA. Other authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}